Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04349410 · ClinicalTrials.gov registry record · Phase 2
The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol
A Phase 2 study, sponsored by The Camelot Foundation.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,800
- Enrollment target
NCT04349410: Completed Phase 2 study, sponsored by The Camelot Foundation.
NCT04349410 is a Phase 2 study that has completed, run by The Camelot Foundation. The registered enrollment target is 1,800 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (1253% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04349410, a Phase 2 study, has completed, sponsored by The Camelot Foundation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,800 participants
- Enrollment target
Study Summary
Diagnostic determination of disease and treatment responses has been limited to qualitative imaging, measurement of serum markers of disease, and sampling of tissue. In each of these instances, there is a built in error either due to sensitivity and specificity issues, clinician interpretation of results, or acceptance of the use of an indirect marker (blood test) of what is happening elsewhere in the body - at the tissue level. The Fleming Method for Tissue and Vascular Differentiation and Metabolism (FMTVDM) using same state single or sequential quantification comparisons \[1\] provides the first and only patented test (#9566037) - along with the associated submitted patent applications ruled to be covered under #9566037 - that quantitatively measures changes in tissue resulting from inter alia a disease process. This includes inter alia coronary artery disease (CAD), cancer and infectious/inflammatory processes including CoVid-19 pneumonia (CVP) resulting from the metabolic and regional blood flow differences (RBFDs) caused by these diseases. The purpose of this paper is to make clinicians and researchers aware of this proposed method for investigating the prevalence and severity of CVP - in addition to providing rapid determination of treatment response in each patient, directing treatment decisions; thereby reducing the loss of time, money, resources and patient lives.
Primary Outcome
Measured improvement in tissue as measured using FMTVDM
Interventions
- DRUG Hydroxychloroquine, Azithromycin
- DRUG Hydroxychloroquine, Doxycycline
- DRUG Hydroxychloroquine, Clindamycin
- DRUG Hydroxychloroquine, Clindamycin, Primaquine - low dose.
- DRUG Hydroxychloroquine, Clindamycin, Primaquine - high dose.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,800 participants |
| Start Date | 2020-04-11 |
| Est. Completion | 2020-09-14 |
| Phase | Phase 2 |
What the finished NCT04349410 record still lists
NCT04349410 is an interventional study that assigns participants to a tested intervention. Its 1,800 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (1253% higher).
The record links to 0 conditions, and to 5 interventions - of which Hydroxychloroquine, Azithromycin is the first listed.
NCT04349410 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04349410 about?
NCT04349410 is a clinical study titled "The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol". Diagnostic determination of disease and treatment responses has been limited to qualitative imaging, measurement of serum markers of disease, and sampling of tissue. In each of these instances, there is a built in error either due to sensitivity and specificity issues, clinician interpretation of re...
What is the current status of trial NCT04349410?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,800 participants. The study started on 2020-04-11. Estimated completion is 2020-09-14.
What interventions are being tested in trial NCT04349410?
The interventions under investigation include: Hydroxychloroquine, Azithromycin (DRUG), Hydroxychloroquine, Doxycycline (DRUG), Hydroxychloroquine, Clindamycin (DRUG), Hydroxychloroquine, Clindamycin, Primaquine - low dose. (DRUG), Hydroxychloroquine, Clindamycin, Primaquine - high dose. (DRUG).
Who is sponsoring clinical trial NCT04349410?
This trial is sponsored by The Camelot Foundation, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04349410's enrollment target sits among peer trials
1,800 10th of 2000 higher than 1,991 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03630055 · 1,800 participants · Phase 3
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
- NCT04475640 · 1,800 participants · NA
Cancer Genetic Testing in Ethnic Populations
- NCT04980794 · 1,800 participants · NA
The Happy Families Project: Testing the Effectiveness of a Conflict Resolution Program for Families
- NCT05258656 · 1,800 participants · NA
Childhood Activities Nutrition and Development Oversight
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI